ATE549020T1 - Pharmazeutische zusammensetzungen enthaltend 1- benzyl-1- hydroxy-2,3-diamino-propylamine, 3- benzyl-3 hydroxy-2-amino-propionsäureamide und verwandte verbindungen als analgetika - Google Patents
Pharmazeutische zusammensetzungen enthaltend 1- benzyl-1- hydroxy-2,3-diamino-propylamine, 3- benzyl-3 hydroxy-2-amino-propionsäureamide und verwandte verbindungen als analgetikaInfo
- Publication number
- ATE549020T1 ATE549020T1 AT10155753T AT10155753T ATE549020T1 AT E549020 T1 ATE549020 T1 AT E549020T1 AT 10155753 T AT10155753 T AT 10155753T AT 10155753 T AT10155753 T AT 10155753T AT E549020 T1 ATE549020 T1 AT E549020T1
- Authority
- AT
- Austria
- Prior art keywords
- benzyl
- hydroxy
- analgesics
- propylamine
- diamino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64727105P | 2005-01-26 | 2005-01-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE549020T1 true ATE549020T1 (de) | 2012-03-15 |
Family
ID=36250723
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT06719390T ATE460159T1 (de) | 2005-01-26 | 2006-01-25 | Verwendung von 1- benzyl-1- hydroxy-2, 3-diamino- propylaminen, 3-benzyl-3 hydroxy-2-amino- propionsäureamiden und verwandten verbindungen als analgetika |
AT10155753T ATE549020T1 (de) | 2005-01-26 | 2006-01-25 | Pharmazeutische zusammensetzungen enthaltend 1- benzyl-1- hydroxy-2,3-diamino-propylamine, 3- benzyl-3 hydroxy-2-amino-propionsäureamide und verwandte verbindungen als analgetika |
AT06719438T ATE523491T1 (de) | 2005-01-26 | 2006-01-25 | 3-heterocyclyl-3-hydroxy-2-amino-propionsäure- amide und damit zusammenhängende verbindungen mit analgesischer und/oder immunostimulatorischer aktivität |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT06719390T ATE460159T1 (de) | 2005-01-26 | 2006-01-25 | Verwendung von 1- benzyl-1- hydroxy-2, 3-diamino- propylaminen, 3-benzyl-3 hydroxy-2-amino- propionsäureamiden und verwandten verbindungen als analgetika |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT06719438T ATE523491T1 (de) | 2005-01-26 | 2006-01-25 | 3-heterocyclyl-3-hydroxy-2-amino-propionsäure- amide und damit zusammenhängende verbindungen mit analgesischer und/oder immunostimulatorischer aktivität |
Country Status (20)
Country | Link |
---|---|
US (11) | US8288556B2 (de) |
EP (7) | EP1841756B1 (de) |
JP (6) | JP5042040B2 (de) |
KR (1) | KR101395382B1 (de) |
CN (2) | CN101151248B (de) |
AT (3) | ATE460159T1 (de) |
AU (4) | AU2006209208B2 (de) |
BR (5) | BRPI0606112B8 (de) |
CA (4) | CA2595544C (de) |
DE (1) | DE602006012801D1 (de) |
DK (3) | DK1841756T3 (de) |
ES (5) | ES2371265T3 (de) |
HK (2) | HK1145628A1 (de) |
HU (1) | HUE028654T2 (de) |
MX (1) | MX2007008955A (de) |
NZ (1) | NZ556614A (de) |
PL (2) | PL383715A1 (de) |
RU (1) | RU2433999C2 (de) |
WO (4) | WO2006081276A1 (de) |
ZA (1) | ZA200706010B (de) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008519840A (ja) | 2004-11-10 | 2008-06-12 | ジェンザイム・コーポレイション | 糖尿病の処置方法 |
WO2006081276A1 (en) | 2005-01-26 | 2006-08-03 | Allergan, Inc. | 3-heteroaryl-3-hydroxy-2-amino-propyl amines and related compounds having analgesic and/or immuno stimulant activity |
EP2923699B1 (de) | 2006-05-09 | 2018-06-20 | Genzyme Corporation | Verfahren zur behandlung von krankhafter fettleber durch hemmung der glucosphingolipid-synthese |
WO2008011487A2 (en) * | 2006-07-19 | 2008-01-24 | Allergan, Inc. | L-benzyl-l-hydr0xy-2, 3-diamin0-propyl amines and 3-benzyl-3-hydroxy-2-amino-propionicacid amides for chronic pain |
WO2008011478A2 (en) * | 2006-07-19 | 2008-01-24 | Allergan, Inc. | Methods for treating chronic pain using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds |
WO2008011485A2 (en) * | 2006-07-19 | 2008-01-24 | Allergan, Inc. | Methods for treating chronic pain |
WO2008011483A2 (en) * | 2006-07-19 | 2008-01-24 | Allergan, Inc. | Methods for treating chronic pain using 1- (hetero) aryl-1-hydroxy 2,3-diamino-propyl amines and related compounds |
WO2008109285A1 (en) * | 2007-03-06 | 2008-09-12 | Allergan, Inc. | Methods for treating cognitive disorders |
ES2383384T3 (es) * | 2007-03-06 | 2012-06-20 | Allergan, Inc. | Un derivado de amidas de ácidos 3-heteroaril-3-hidroxi-2-aminopropiónicos específico para su uso en el tratamiento de ciertos trastornos cognitivos |
US9314466B2 (en) | 2007-03-06 | 2016-04-19 | Allergan, Inc. | Methods for treating cognitive disorders using 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds |
US20140179925A1 (en) | 2009-09-04 | 2014-06-26 | Allergan, Inc. | Methods for treating cognitive disorders using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds |
CN101279955B (zh) * | 2007-04-03 | 2012-11-28 | 北京摩力克科技有限公司 | 作为二肽肽激酶-iv抑制剂的n-取代硫吗啉衍生物及其医药用途 |
US8304447B2 (en) | 2007-05-31 | 2012-11-06 | Genzyme Corporation | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors |
BRPI0813832A2 (pt) | 2007-07-17 | 2015-01-06 | Allergan Inc | Métodos para tratamento da ansiedade |
MX2010003603A (es) | 2007-10-05 | 2010-06-02 | Genzyme Corp | Metodo para el tratamiento de enfermedades de riñon poliquisticas con derivados de ceramida. |
US8168631B2 (en) | 2008-02-05 | 2012-05-01 | Allergan, Inc. | 3-(4-fluorophenyl)-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic activity |
EP2320886B1 (de) | 2008-07-28 | 2017-06-28 | Genzyme Corporation | Glucosylceramid-synthase-hemmung zur behandlung von kollabierender glomerulopathie und anderen glomerulären erkrankungen |
US8309593B2 (en) * | 2008-10-03 | 2012-11-13 | Genzyme Corporation | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors |
BR112012001047A2 (pt) | 2009-07-17 | 2019-09-24 | Allergan Inc | composições compreendendo um inibidor de colinesterase para tratar distúrbios cognitivos |
EP2477623A1 (de) * | 2009-09-16 | 2012-07-25 | Allergan, Inc. | Zusammensetzungen und verfahren zur behandlung von störungen der gastrointestinalen motilität |
BR112012006073A2 (pt) | 2009-09-16 | 2016-05-31 | Allergan Inc | composições e métodos para tratar espasticidade. |
JP2013505248A (ja) | 2009-09-16 | 2013-02-14 | アラーガン インコーポレイテッド | 発作性疾患を治療するための組成物及び方法 |
KR20130010456A (ko) * | 2009-11-18 | 2013-01-28 | 에프에이비 파마 에스에이에스 | 신규의 헤테로사이클릭 아크릴아미드 및 약제로서 이의 용도 |
SI3033327T1 (en) * | 2013-08-15 | 2018-05-31 | Allergan, Inc. | (-) - (2R, 3S) -2-AMINO-3-HYDROXY-3-PYRIDIN-4-YL-1-PYROLIDIN-1-ILL- PROPAN- 1-ON (L) - (+) TARTRATED SOLE AND METHOD FOR ITS PRODUCTION AND ITS USE |
TWI690511B (zh) | 2013-09-20 | 2020-04-11 | 美商拜奧馬林製藥公司 | 用於治療疾病之葡萄糖苷基腦醯胺(glucosylceramide)合成酶抑制劑 |
JP6152816B2 (ja) * | 2014-03-26 | 2017-06-28 | ソニー株式会社 | 半導体デバイス、表示パネル、表示装置、電子装置、および、半導体デバイスの製造方法 |
DE102015217629A1 (de) * | 2015-09-15 | 2017-03-16 | Tridonic Gmbh & Co Kg | PFC-Modul für lückenden Betrieb |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2514380A (en) * | 1946-12-26 | 1950-07-11 | Hoffmann La Roche | Diamines and method of production |
DE1001261C2 (de) * | 1954-08-05 | 1957-07-04 | Thomae Gmbh Dr K | Verfahren zur Herstellung von basischen Estern endocyclisch substituierter Mandelsaeuren und ihren Salzen |
US2918466A (en) * | 1955-05-24 | 1959-12-22 | Univ St Johns | Antimicrobial chemical compounds derived from alkoxyphenyl glycidic acid |
US3065265A (en) * | 1957-07-04 | 1962-11-20 | Hoffmann La Roche | Amino acid hydrazides |
SU1063026A1 (ru) | 1982-05-19 | 1990-12-07 | Институт биохимии АН ЛитССР | N @ -Бензолсульфонильные производные трес-DL-фенилсерина, обладающие противовоспалительной активностью |
EP0144290A3 (de) * | 1983-12-01 | 1987-05-27 | Ciba-Geigy Ag | Substituierte Aethylendiaminderivate |
JPS60132935A (ja) | 1983-12-20 | 1985-07-16 | Sumitomo Chem Co Ltd | フエニルセリン誘導体及びその製造方法 |
JPS61145148A (ja) | 1984-12-19 | 1986-07-02 | Sumitomo Seiyaku Kk | フエニルセリン誘導体 |
GB8618188D0 (en) * | 1986-07-25 | 1986-09-03 | Ici Plc | Diamine compounds |
GB8622352D0 (en) * | 1986-09-17 | 1986-10-22 | Zambeleetti Spa Dr L | Compounds |
JPH02250845A (ja) | 1989-03-22 | 1990-10-08 | Sumitomo Pharmaceut Co Ltd | 3―(4―フルオロフェニル)プロピオンアルデヒドの製造方法 |
EP0522606B1 (de) * | 1991-05-10 | 1996-04-03 | Takeda Chemical Industries, Ltd. | Pyridinderivate, deren Herstellung und Anwendung |
JPH0550499A (ja) | 1991-08-27 | 1993-03-02 | Kuwabara Yasunaga | 成形型内におけるトリミング方法及び容器 |
US6696486B1 (en) * | 1992-01-22 | 2004-02-24 | Glaxo Group Limited | Medical use for atypical β-adrenoceptor agonists |
AU676361B2 (en) | 1993-08-13 | 1997-03-06 | Seikagaku Corporation | Remedy for nervous diseases |
EP0734453A1 (de) | 1993-12-17 | 1996-10-02 | Dsm N.V. | Phenylserinamide und die herstellung von phenylserinen/phenylserinamiden |
AU698833B2 (en) | 1994-06-10 | 1998-11-12 | Seikagaku Corporation | 2-acylaminopropanol compound and medical composition |
EP0782631A4 (de) * | 1994-09-19 | 1999-03-24 | Univ Leland Stanford Junior | Behandlung gegen plasmodium |
US5585388A (en) * | 1995-04-07 | 1996-12-17 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acetylcholine receptors |
FR2732894B1 (fr) | 1995-04-13 | 1997-07-04 | Sanofi Sa | Nouvelle utilisation de composes agonistes beta9-adrenergiques |
JPH08337569A (ja) * | 1995-06-15 | 1996-12-24 | Sankyo Co Ltd | 鎮痛活性物質 |
WO2001004108A1 (en) | 1999-07-09 | 2001-01-18 | Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
WO1997010817A1 (en) * | 1995-09-20 | 1997-03-27 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
NO965193L (no) * | 1995-12-08 | 1997-06-09 | Seikagaku Kogyo Kk Seikagaku C | Aminalkoholderivat og fremgangsmåte for fremstilling derav |
JP3993908B2 (ja) * | 1995-12-08 | 2007-10-17 | 生化学工業株式会社 | アミノアルコール誘導体及び該誘導体の製造方法 |
DE19601745C1 (de) | 1996-01-19 | 1997-10-09 | Gruenenthal Gmbh | Verfahren zur Racematspaltung von Tramadol |
EP0848059A1 (de) * | 1996-12-12 | 1998-06-17 | Vetigen | ICYP (Iodocyanopindolol) Rezeptor von Säugetieren und dessen Anwendungen |
WO1998033501A1 (en) * | 1997-01-31 | 1998-08-06 | Avid Therapeutics Inc. | 2-benzoylamino-3-phenylpropenamide derivatives and methods of using the same |
US6573387B1 (en) * | 1997-03-21 | 2003-06-03 | The Scripps Research Institute | Synthesis of α,β-substituted amino amides, esters, and acids |
JP4036500B2 (ja) | 1997-05-23 | 2008-01-23 | 生化学工業株式会社 | アミノアルコール誘導体及びそれを含有する医薬 |
US6617340B1 (en) * | 1999-07-29 | 2003-09-09 | Novartis Ag | N-(substituted glycyl)-pyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
SE9904197D0 (sv) | 1999-11-22 | 1999-11-22 | Amersham Pharm Biotech Ab | A method for anion exchange adsorption on matrices carrying mixed mode ligands |
US6407064B2 (en) | 1999-12-06 | 2002-06-18 | Seikagaku Corporation | Aminoalcohol derivative and medicament comprising the same |
US20030199571A1 (en) * | 1999-12-24 | 2003-10-23 | Gordon Bruton | (Hetero) Bicyclymethanesulfonylamino-substituted hydroxamic acid derivatives |
US6380398B2 (en) * | 2000-01-04 | 2002-04-30 | Novo Nordisk A/S | Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV |
GB0010188D0 (en) * | 2000-04-26 | 2000-06-14 | Ferring Bv | Inhibitors of dipeptidyl peptidase IV |
KR20000063913A (ko) | 2000-08-10 | 2000-11-06 | 하현준 | 아지리딘으로부터 1,2-디아미노프로판 알코올을 제조하는방법 |
US20020198240A1 (en) * | 2001-01-10 | 2002-12-26 | Shayman James A. | Amino ceramide - like compounds and therapeutic methods of use |
BR0206400A (pt) | 2001-01-10 | 2005-01-18 | Univ Michigan | Compostos de amino ceramidas e seus usos em métodos terapêuticos |
ES2399323T3 (es) * | 2001-07-16 | 2013-03-27 | Genzyme Corporation | Síntesis de inhibidores de la UDP-glucosa:N-acilesfingosina glucosiltransferasa |
CA2462200A1 (en) * | 2001-08-10 | 2003-02-20 | Palatin Technologies, Inc. | Peptidomimetics of biologically active metallopeptides |
AU2002348261A1 (en) * | 2001-11-26 | 2003-06-10 | Genzyme Corporation | Diastereoselective synthesis of udp-glucose : n-acylsphingosine glucosyltransferase inhibitors |
JP2006021997A (ja) | 2002-07-09 | 2006-01-26 | Ono Pharmaceut Co Ltd | cysLT1/cysLT2両受容体拮抗性呼吸器疾患治療剤 |
US7309714B2 (en) * | 2002-12-04 | 2007-12-18 | Merck & Co., Inc. | Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
CA2851462A1 (en) | 2003-01-08 | 2004-07-29 | University Of Washington | Antibacterial agents |
KR101146849B1 (ko) * | 2003-12-11 | 2012-05-16 | 미쓰비시 타나베 파마 코퍼레이션 | α-아미노산 유도체 및 그 의약 용도 |
AU2004308966A1 (en) * | 2003-12-23 | 2005-07-14 | Musc Foundaton For Research Development | Methods and compositions for the prevention and treatment of inflammatory diseases or conditions |
US20070093492A1 (en) * | 2004-03-09 | 2007-04-26 | Weir-Torn Jiaang | Pyrrolidine derivatives |
US20080221203A1 (en) | 2004-08-09 | 2008-09-11 | University Catholique De Louvain | Use of Agonists and Antagonists of Beta Adrenoceptors for Treating Arterial Disease |
DE102004053409A1 (de) | 2004-11-05 | 2006-05-11 | Bayer Healthcare Ag | Verfahren zur gezielten Herstellung von Lysobactinfragmenten |
WO2006081276A1 (en) * | 2005-01-26 | 2006-08-03 | Allergan, Inc. | 3-heteroaryl-3-hydroxy-2-amino-propyl amines and related compounds having analgesic and/or immuno stimulant activity |
US7858825B2 (en) * | 2007-02-15 | 2010-12-28 | Colorado State University Research Foundation | Acid and base stable diphenylmethanol derivatives and methods of use |
WO2008109286A1 (en) * | 2007-03-06 | 2008-09-12 | Allergan, Inc. | Methods for treating cognitive disorders using 1-aryl-1-hydroxy-2,3-diamino-propyl amines, 1-heteroaryl-1-hydroxy-2,3-diamino-propyl amines and related compounds |
WO2008109285A1 (en) * | 2007-03-06 | 2008-09-12 | Allergan, Inc. | Methods for treating cognitive disorders |
ES2383384T3 (es) * | 2007-03-06 | 2012-06-20 | Allergan, Inc. | Un derivado de amidas de ácidos 3-heteroaril-3-hidroxi-2-aminopropiónicos específico para su uso en el tratamiento de ciertos trastornos cognitivos |
BRPI0813832A2 (pt) * | 2007-07-17 | 2015-01-06 | Allergan Inc | Métodos para tratamento da ansiedade |
US8168631B2 (en) | 2008-02-05 | 2012-05-01 | Allergan, Inc. | 3-(4-fluorophenyl)-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic activity |
WO2009142969A1 (en) * | 2008-05-20 | 2009-11-26 | Allergan, Inc. | Therapeutic lactams |
EP2477623A1 (de) * | 2009-09-16 | 2012-07-25 | Allergan, Inc. | Zusammensetzungen und verfahren zur behandlung von störungen der gastrointestinalen motilität |
JP2013505248A (ja) * | 2009-09-16 | 2013-02-14 | アラーガン インコーポレイテッド | 発作性疾患を治療するための組成物及び方法 |
BR112012006073A2 (pt) * | 2009-09-16 | 2016-05-31 | Allergan Inc | composições e métodos para tratar espasticidade. |
-
2006
- 2006-01-25 WO PCT/US2006/002570 patent/WO2006081276A1/en active Application Filing
- 2006-01-25 PL PL383715A patent/PL383715A1/pl unknown
- 2006-01-25 NZ NZ556614A patent/NZ556614A/en unknown
- 2006-01-25 BR BRPI0606112A patent/BRPI0606112B8/pt active IP Right Grant
- 2006-01-25 BR BR122018068138A patent/BR122018068138B8/pt active IP Right Grant
- 2006-01-25 US US11/814,598 patent/US8288556B2/en active Active
- 2006-01-25 DK DK06719438.1T patent/DK1841756T3/da active
- 2006-01-25 EP EP06719438A patent/EP1841756B1/de active Active
- 2006-01-25 ES ES06719438T patent/ES2371265T3/es active Active
- 2006-01-25 CN CN2006800098658A patent/CN101151248B/zh active Active
- 2006-01-25 DK DK06719422.5T patent/DK1841743T3/en active
- 2006-01-25 AT AT06719390T patent/ATE460159T1/de not_active IP Right Cessation
- 2006-01-25 WO PCT/US2006/002580 patent/WO2006081280A1/en active Application Filing
- 2006-01-25 JP JP2007553191A patent/JP5042040B2/ja not_active Expired - Fee Related
- 2006-01-25 PL PL06719422T patent/PL1841743T3/pl unknown
- 2006-01-25 ES ES06719433.2T patent/ES2436612T3/es active Active
- 2006-01-25 CN CN201210113463.XA patent/CN102718748B/zh active Active
- 2006-01-25 BR BRPI0606111A patent/BRPI0606111B8/pt active IP Right Grant
- 2006-01-25 AT AT10155753T patent/ATE549020T1/de active
- 2006-01-25 BR BRPI0607304-2A patent/BRPI0607304A2/pt not_active Application Discontinuation
- 2006-01-25 EP EP06719422.5A patent/EP1841743B1/de active Active
- 2006-01-25 DE DE602006012801T patent/DE602006012801D1/de active Active
- 2006-01-25 ES ES10155753T patent/ES2380904T3/es active Active
- 2006-01-25 US US11/814,604 patent/US20090088433A1/en not_active Abandoned
- 2006-01-25 CA CA2595544A patent/CA2595544C/en not_active Expired - Fee Related
- 2006-01-25 CA CA2595519A patent/CA2595519C/en not_active Expired - Fee Related
- 2006-01-25 CA CA2595522A patent/CA2595522C/en active Active
- 2006-01-25 JP JP2007553188A patent/JP5042039B2/ja active Active
- 2006-01-25 EP EP06719433.2A patent/EP1841742B1/de active Active
- 2006-01-25 EP EP12161266.7A patent/EP2489658B1/de active Active
- 2006-01-25 JP JP2007553193A patent/JP5107058B2/ja active Active
- 2006-01-25 EP EP10155753A patent/EP2198864B1/de active Active
- 2006-01-25 RU RU2007128313/04A patent/RU2433999C2/ru active
- 2006-01-25 US US11/814,601 patent/US8013000B2/en active Active
- 2006-01-25 AT AT06719438T patent/ATE523491T1/de not_active IP Right Cessation
- 2006-01-25 WO PCT/US2006/002557 patent/WO2006081273A1/en active Application Filing
- 2006-01-25 WO PCT/US2006/002505 patent/WO2006081252A2/en active Application Filing
- 2006-01-25 KR KR1020077019382A patent/KR101395382B1/ko active IP Right Grant
- 2006-01-25 HU HUE06719422A patent/HUE028654T2/en unknown
- 2006-01-25 EP EP12159632.4A patent/EP2474534B1/de active Active
- 2006-01-25 BR BRPI0607379A patent/BRPI0607379B8/pt active IP Right Grant
- 2006-01-25 ES ES06719390T patent/ES2340196T3/es active Active
- 2006-01-25 ES ES06719422.5T patent/ES2565236T3/es active Active
- 2006-01-25 AU AU2006209208A patent/AU2006209208B2/en not_active Ceased
- 2006-01-25 AU AU2006209207A patent/AU2006209207C1/en not_active Ceased
- 2006-01-25 AU AU2006209197A patent/AU2006209197A1/en not_active Abandoned
- 2006-01-25 AU AU2006209209A patent/AU2006209209B2/en active Active
- 2006-01-25 JP JP2007553179A patent/JP5039564B2/ja not_active Expired - Fee Related
- 2006-01-25 CA CA002595542A patent/CA2595542A1/en not_active Abandoned
- 2006-01-25 DK DK06719390.4T patent/DK1841423T3/da active
- 2006-01-25 US US11/814,593 patent/US8153666B2/en active Active
- 2006-01-25 EP EP06719390A patent/EP1841423B1/de active Active
- 2006-01-25 MX MX2007008955A patent/MX2007008955A/es active IP Right Grant
-
2007
- 2007-07-20 ZA ZA200706010A patent/ZA200706010B/xx unknown
-
2010
- 2010-12-22 HK HK10111996.9A patent/HK1145628A1/xx not_active IP Right Cessation
-
2011
- 2011-08-02 US US13/196,132 patent/US8513288B2/en active Active
-
2012
- 2012-03-01 US US13/409,853 patent/US8835463B2/en active Active
- 2012-04-04 JP JP2012085680A patent/JP2012162547A/ja active Pending
- 2012-04-04 JP JP2012085676A patent/JP2012162546A/ja active Pending
- 2012-04-19 US US13/450,854 patent/US9278943B2/en active Active
- 2012-09-12 US US13/612,260 patent/US8431599B2/en active Active
-
2013
- 2013-01-09 HK HK13100295.7A patent/HK1173721A1/xx unknown
- 2013-03-15 US US13/834,336 patent/US8927589B2/en active Active
- 2013-07-24 US US13/949,468 patent/US9399628B2/en active Active
-
2015
- 2015-11-30 US US14/954,263 patent/US9828349B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE549020T1 (de) | Pharmazeutische zusammensetzungen enthaltend 1- benzyl-1- hydroxy-2,3-diamino-propylamine, 3- benzyl-3 hydroxy-2-amino-propionsäureamide und verwandte verbindungen als analgetika | |
ATE473975T1 (de) | Chemische verbindungen | |
ATE398613T1 (de) | Chemische verbindungen | |
CY1111190T1 (el) | Παραγωγα μαλεϊμιδιου, φαρμακευτικες συνθεσεις και μεθοδοι για την θεραπεια καρκινου | |
CY1109962T1 (el) | Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4,5]δεκαν-2-ονης για τη θεραπεια παχυσαρκιας | |
BRPI0607728A2 (pt) | complexo de lipoproteìna carregado reconstituìdo, composição farmacêutica, e, uso de um complexo de lipoproteìna carregado | |
ATE476446T1 (de) | Acylierte glp-1 verbindungen | |
MY140514A (en) | Triazolopyridine derivatives as inhibitors of lipases and phospholipases | |
CY1109366T1 (el) | Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4.5]δεκαν-2-ονης | |
BRPI0509660A (pt) | compostos de beta-carbolina de utilidade no tratamento de doenças inflamatórias | |
MX2008001560A (es) | Nuevos compuestos analogos de la camptotecina, un procedimiento para su preparacion y composiciones farmaceuticas que los contienen. | |
NO20085317L (no) | Imidazoazepinonforbindelser | |
CY1112555T1 (el) | Διεργασια χημικης συζευξης με ενα παραγωγο φαινυλ βορονικου οξεος | |
ATE498600T1 (de) | Inden derivate als pharmazeutika | |
ATE514698T1 (de) | Tetracyclische azapyrazinoindoline als 5-ht2- liganden | |
WO2014012074A3 (en) | No-releasing nonoate (nitrogen-bound) sulfonamide-linked-coxib anti-cancer agents | |
CY1109541T1 (el) | Φαρμακευτικη συνταγοποιηση για την θεραπεια οστεοαρθριτιδας η οποια περιεχει κλοδρονικο οξυ και υαλουρονικο οξυ | |
DE602007002716D1 (de) | Neuroprotektive verbindungen und deren verwendungen | |
EA201000611A1 (ru) | 4,4-дизамещенные пиперидины | |
TW200613282A (en) | Organic compounds | |
UA95254C2 (ru) | Соединения аналога камптотецина, способ их получения и фармацевтическая композиция, которая их содержит |